Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC5 | P28715 | 1/20 | 0.51 |
| ▸ | FEN1 | P39748 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | ALPL | P05186 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5161664 | 0.84 | ERCC5 (0.54) | ERCC5FEN1NPC1RAB9ATP53 | |
| SCHEMBL6320074 | 0.76 | ERCC5 (0.74) | ERCC5FEN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5036990 | 0.75 | NPC1 (0.63) | NPC1RAB9ASMN1; SMN2GAANPSR1 | |
| SCHEMBL27986049 | 0.74 | ALDH1A1 (0.49) | ERCC5FEN1NPC1RAB9AHPGD | |
| SCHEMBL7070914 | 0.74 | ERCC5 (0.71) | ERCC5FEN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4459612 | 0.74 | ERCC5 (0.61) | ERCC5FEN1NPC1RAB9ATP53 | |
| SCHEMBL183688 | 0.73 | ERCC5 (0.65) | ERCC5FEN1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL7641023 | 0.72 | CES2 (0.59) | NPC1RAB9ATP53SMN1; SMN2GAA | |
| SCHEMBL3836768 | 0.72 | ERCC5 (0.54) | ERCC5FEN1NPC1RAB9ATP53 | |
| SCHEMBL10356158 | 0.72 | ERCC5 (0.62) | ERCC5FEN1RAB9ATP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1308441-B1 | 2-AMINOPYRIDINE COMPOUNDS AND USE THEREOF AS DRUGS | EISAI R&D MAN CO LTD (JP) | 2009-10-07 | — | — | EP | disclosed |
| EP-1308441-B1 | 2-AMINOPYRIDINE COMPOUNDS AND USE THEREOF AS DRUGS | EISAI R&D MAN CO LTD (JP) | 2009-10-07 | — | — | EP | disclosed |
| US-6750232-B2 | ADENOSINE ANTAGONIST; AN IMPORTANT REGULATORY FACTOR INVOLVED IN VARIOUS INTRACELLULAR METABOLISMS SUCH AS REGULATION OF ENERGY LEVELS | EISAI CO., LTD. (JP) | 2004-06-15 | — | — | US | disclosed |
| US-20040006082-A1 | 2-Aminopyridine compounds and use thereof as drugs | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-01-08 | — | — | US | disclosed |
| CN-1446202-A | 2-aminopyridine compounds and use thereof as drugs | EISAI CO LTD (JP) | 2003-10-01 | — | — | CN | disclosed |
| EP-1308441-A1 | 2-AMINOPYRIDINE COMPOUNDS AND USE THEREOF AS DRUGS | Eisai Co., Ltd. (JP) | 2003-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006082-A1 | 2-Aminopyridine compounds and use thereof as drugs | ADORA1, ADORA2B, ADORA2A | ERCC5 3165/4885FEN1 3395/4885NPC1 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.